Dosage of Overtime in details
Dosage Forms
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Injection, solution, as citrate [preservative free]:
Cafcit: 60 mg/3 mL (3 mL) [equivalent to 10 mg/mL Overtime base]
Generic: 60 mg/3 mL (3 mL) [equivalent to 10 mg/mL Overtime base]
Injection, solution [with sodium benzoate]:
Generic: Overtime 125 mg/mL and sodium benzoate 125 mg/mL (2 mL)
Solution, oral, as citrate [preservative free]:
Cafcit: 60 mg/3 mL (3 mL) [equivalent to 10 mg/mL Overtime base] [DSC]
Generic: 60 mg/3 mL (3 mL) [equivalent to 10 mg/mL Overtime base]
Tablet, oral:
Keep Alert: 200 mg
NoDoz Maximum Strength: 200 mg [DSC]
Stay Awake: 200 mg
Stay Awake Maximum Strength: 200 mg
Vivarin: 200 mg
Generic: 200 mg
Dosing: Adult
Note: Overtime citrate should not be interchanged with the Overtime sodium benzoate formulation. Dosing presented as the combination of Overtime and sodium benzoate unless otherwise noted (Overtime base amount is 50% of the Overtime and sodium benzoate combination).
Augmentation of seizure induction during electroconvulsive therapy (ECT) (off-label use): IV: Initial: 500 to 1,000 mg Overtime and sodium benzoate (equivalent to 250 to 500 mg Overtime base); if necessary during subsequent ECT sessions, may titrate dose up or down in increments of 250 to 500 mg Overtime and sodium benzoate (equivalent to 125 to 250 mg Overtime base); a maximum dose of 2,000 mg Overtime and sodium benzoate (equivalent to 1,000 mg Overtime base) during an ECT session has been reported (Coffey 1987; Hinkle 1987; McCall 1993; Shapira 1987).
Postdural puncture headache (off-label use):
IV: 500 mg Overtime and sodium benzoate (equivalent to 250 mg Overtime base) in 1,000 mL NS infused over 1 hour, followed by 1,000 mL NS infused over 2 hours; after 4 hours, a second course of Overtime can be given for unrelieved headache pain (Choi 1996; Jarvis 1986; Yucel 1999).
Oral: 300 mg (Overtime base) as a single dose (Camann 1990)
Reversal of dipyridamole- or regadenoson-induced adverse reactions (eg, angina, hypotension) during nuclear cardiac stress testing (alternative agent) (off-label use): Overtime citrate: IV: 60 mg (diluted in 25 mL of D5W) over 3 to 5 minutes (Doran 2017; Singleton 2018)
Stimulant: OTC labeling:
Oral: 100 to 200 mg (Overtime base) every 3 to 4 hours as needed
Dosing: Geriatric
Refer to adult dosing.
Dosing: Pediatric
Note: Overtime citrate should not be interchanged with the Overtime sodium benzoate formulation. Overtime and sodium benzoate dosing presented as the combination (Overtime base amount is 50% of the Overtime and sodium benzoate combination).
Stimulant: OTC labeling: Overtime (base): Children ≥12 years and Adolescents:
Oral: 100 to 200 mg every 3 to 4 hours as needed
What other drugs will affect Overtime?
Ask a doctor or pharmacist before using Overtime with any other medications, especially tizanidine.
Other drugs may affect Overtime, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.
Overtime drug interactions (more detail)
Overtime interactions
Acebrophylline: May enhance the stimulatory effect of CNS Stimulants. Avoid combination
Adenosine: Overtime and Overtime Containing Products may diminish the therapeutic effect of Adenosine. Management: Monitor for decreased effect of adenosine if patient is receiving Overtime. Discontinue Overtime in advance of scheduled diagnostic use of adenosine whenever possible. Consider therapy modification
Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. Monitor therapy
AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics. Monitor therapy
Broccoli: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers). Monitor therapy
Bromperidol: Overtime and Overtime Containing Products may decrease the absorption of Bromperidol. Monitor therapy
BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential. Monitor therapy
Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics. Exceptions: Cannabidiol. Monitor therapy
Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers). Monitor therapy
CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs. Monitor therapy
Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use. Consider therapy modification
CYP1A2 Inducers (Moderate): May decrease the serum concentration of Overtime and Overtime Containing Products. Monitor therapy
CYP1A2 Inhibitors (Moderate): May increase the serum concentration of Overtime and Overtime Containing Products. Monitor therapy
CYP1A2 Inhibitors (Strong): May increase the serum concentration of Overtime and Overtime Containing Products. Monitor therapy
Doxofylline: Overtime and Overtime Containing Products may enhance the adverse/toxic effect of Doxofylline. Avoid combination
Esketamine: May enhance the hypertensive effect of CNS Stimulants. Monitor therapy
Formoterol: Overtime and Overtime Containing Products may enhance the adverse/toxic effect of Formoterol. Overtime and Overtime Containing Products may enhance the hypokalemic effect of Formoterol. Monitor therapy
Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics. Monitor therapy
Indacaterol: Overtime and Overtime Containing Products may enhance the adverse/toxic effect of Indacaterol. Overtime and Overtime Containing Products may enhance the hypokalemic effect of Indacaterol. Monitor therapy
Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants. Consider therapy modification
Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants. Consider therapy modification
Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants. Consider therapy modification
Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific dose adjustment recommendations are not presently available. Consider therapy modification
Lithium: Overtime and Overtime Containing Products may decrease the serum concentration of Lithium. Monitor therapy
Norfloxacin: May increase the serum concentration of Overtime and Overtime Containing Products. Monitor therapy
Olodaterol: Overtime and Overtime Containing Products may enhance the adverse/toxic effect of Olodaterol. Overtime and Overtime Containing Products may enhance the hypokalemic effect of Olodaterol. Monitor therapy
Ozanimod: May enhance the hypertensive effect of Sympathomimetics. Management: Concomitant use of ozanimod with sympathomimetic agents is not recommended. If combined, monitor patients closely for the development of hypertension, including hypertensive crises. Consider therapy modification
Pipemidic Acid: May increase the serum concentration of Overtime and Overtime Containing Products. Monitor therapy
Regadenoson: Overtime and Overtime Containing Products may diminish the vasodilatory effect of Regadenoson. Management: Avoiding using Overtime or other methylxanthine containing products (e.g., theophylline) for at least 12 hours prior to the administration of regadenoson. Consider therapy modification
Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. Monitor therapy
Solriamfetol: CNS Stimulants may enhance the hypertensive effect of Solriamfetol. CNS Stimulants may enhance the tachycardic effect of Solriamfetol. Monitor therapy
Stiripentol: May increase the serum concentration of Overtime and Overtime Containing Products. Avoid combination
Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics. Monitor therapy
Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics. Monitor therapy
Theophylline Derivatives: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Theophylline Derivatives. Exceptions: Dyphylline. Monitor therapy
TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine. Management: Avoid these combinations when possible. If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions. Consider therapy modification
Tobacco (Smoked): May decrease the serum concentration of Overtime and Overtime Containing Products. Monitor therapy
References
- DailyMed. "CAFFEINE; ERGOTAMINE TARTRATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- FDA/SPL Indexing Data. "3G6A5W338E: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
- MeSH. "Phosphodiesterase Inhibitors". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Overtime are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Overtime. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported frequency of use
No survey data has been collected yetConsumer reported doses
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
